{
    "clinical_study": {
        "@rank": "26872", 
        "arm_group": {
            "arm_group_label": "Tolcapone", 
            "arm_group_type": "Experimental", 
            "description": "Tasmar"
        }, 
        "brief_summary": {
            "textblock": "In this study, pharmacologic effects of COMT inhibition during sleep deprivation in healthy\n      subjects in dependence of their Val158Met genotype of COMT are studied. Potential effects\n      are identified by measurement of vigilance and cognitive performance as well as EEG\n      measurements during wake and sleep.\n\n        -  Trial with medicinal product"
        }, 
        "brief_title": "Role of the Catechol-O-methyltransferase (COMT) in the Physiological Regulation of Vigilance", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Healthy male subjects\n\n          -  Age: 20-30 years\n\n          -  written informed consent\n\n          -  right handed\n\n          -  non smoker\n\n        Exclusion criteria:\n\n          -  sleep disturbances\n\n          -  irregular sleep-wake rhythm\n\n          -  travelling with time-shift\n\n          -  liver diseases (ALT: > 82 U/l; AST: > 76 U/l)\n\n          -  diseases of the nervous system\n\n          -  acute internal medicine diseases\n\n          -  medication or drug abuse\n\n          -  intake of more than 3 caffeine-containing drinks\n\n          -  intake of more than 5 alcoholic drinks per week\n\n          -  heart pacemaker or implanted medical devices\n\n          -  Body-Mass-Index (BMI): 20< BMI >26"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "30 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02080715", 
            "org_study_id": "COMT and vigilance"
        }, 
        "intervention": [
            {
                "arm_group_label": "Tolcapone", 
                "description": "2 x 100mg Tolcapone compared to placebo (randomized, double-blind, cross-over)", 
                "intervention_name": "Tolcapone", 
                "intervention_type": "Drug", 
                "other_name": "Tasmar"
            }, 
            {
                "arm_group_label": "Tolcapone", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Tolcapone"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Sleep-wake", 
            "regulation", 
            "volunteers"
        ], 
        "lastchanged_date": "March 5, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Zurich", 
                    "country": "Switzerland"
                }, 
                "name": "University of Zurich, Institute of Pharmacology and Toxicology"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Switzerland"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Randomized, Double-blind, Placebo-controlled Examination of the Effects of Tolcapone (TASMAR) on Vigilance in Healthy Volunteers After Sleep Deprivation", 
        "overall_contact": {
            "email": "michael.sommerauer@usz.ch", 
            "last_name": "Michael Sommerauer, MD", 
            "phone": "+41 (0)44 255 11 11"
        }, 
        "overall_contact_backup": {
            "email": "landolt@pharma.uzh.ch", 
            "last_name": "Hans-Peter Landolt, Professor"
        }, 
        "overall_official": [
            {
                "affiliation": "University of Zurich, Institute of Pharmacology and Toxicology", 
                "last_name": "Hans-Peter Landolt, Professor", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "University Hospital Zurich, Department of Neurology", 
                "last_name": "Christian Baumann, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Switzerland: Swissmedic", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Vigilance is measured subjectively (questionnaires and visual analogue scales) and objectively (e.g., psychomotor vigilance task: reaction times and number of lapses; waking EEG: spectral power) at 3-hour intervals during 40 hours prolonged wakefulness in 30 healthy male adults.", 
            "measure": "Evolution of vigilance during prolonged wakefulness after intake of tolcapone when compared to placebo", 
            "safety_issue": "No", 
            "time_frame": "Participants will be studied during two weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02080715"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University of Zurich", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Zurich", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}